Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes by Ménétrier-Caux, C et al.
Although immunotherapy with IL-2 and/or interferon a (IFN-a)
yields objective response in 15% of patients with metastatic renal
cell carcinoma, a majority of these patients will still experience
progressive disease despite immunotherapy (Rosenberg et al,
1989; Négrier et al, 1996). This may result from the lack of
tumour-specific antigens in most of these tumours, a defective
tumour-specific antigen presentation and/or the production of
immunosuppressive factors by RCC.
IL-10 is a potent immunosuppressive cytokine produced by B
lymphocytes, monocytes/macrophages as well as Th0 and Th2
T-cell subsets (Howard and O’Garra, 1992). IL-10 inhibits the
proliferation and the production of IL-2 and IFN-g by human
peripheral blood T lymphocytes and T-cell clones (de Waal Malefyt
et al, 1993; Taga et al, 1993) and suppresses the secretion of IL-1,
IL-6, IL-8 and TNF-a (Fiorentino et al, 1991). In addition, IL-10
induces the generation of CD4+ T cells that are capable of blocking
the proliferation of Ag-specific T-cell clones (Groux et al, 1997).
The production of IL-10 mRNA or protein has been reported in
RCC, as well as in other tumours, in particular ovarian tumours and
non-Hodgkin’s lymphoma (NHL), suggesting a possible local
immunosuppressive effect of this cytokine in vivo (Benjamin et al,
1992; Emilie et al, 1992; Pisa et al, 1992; Blay et al, 1993; Filgueira
et al, 1993; Gastl et al, 1993; Mauerer et al, 1995; Wang et al, 1995;
Nakagomi et al, 1995; Voorzanger et al, 1996).
The objectives of this study were to investigate the possible
production of immunosuppressive mediators by RCC tumours, in
particular IL-10. The results presented here show that IL-10 protein
is detectable in vivo in RCC tumour samples and that RCC cell
lines induce the production of TNF-a, IL-10 and PGE2 by autolo-
gous and allogeneic monocytes in vitro. TNF-a, IL-10 and PGE2
are responsible for the down-regulation of HLA-DR and CD86
expression at the cell surface, as well as for the decrease in the
endocytic capacities of monocytes induced by RCC CM in vitro.
MATERIALS AND METHODS
Cell lines and tumour samples
Clear cell renal carcinoma cells were obtained after therapeutic
surgery of the primary tumour in 21 patients. Each tumour sample
was divided into four fragments, representative of the tumour, as
evaluated by examination of a frozen section, for (1) histological
analysis, (2) molecular analysis, (3) storage in isopentane at
–180°C for immunological analysis and (4) mechanical and
enzymatic disaggregation to obtain tumour cells for culture. Four
RCC cell lines (CAN, CHA, GUI, VER) previously characterized
(Bain et al, 1996) and two primary cell cultures (LEC, DUF) were
obtained from these 21 tumours. Primary culture of normal renal
epithelial cells (CAN nor) was obtained after enzymatic disaggre-
gation of normal tissue surrounding the tumour. In addition, RCC
cell lines (Caki-1, Caki-2, ACHN, A-704) and breast carcinoma
cell lines used as control (SKBR-3, T47-D, MCF-7) were obtained
from the American Type Cell Collection (ATCC) (Rockville, MD,
USA). All cell lines were cultured in complete RPMI-1640
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Summary Immunotherapy with interleukin 2 (IL-2) is not an effective anti-cancer treatment in the majority of patients with renal cell carcinoma
(RCC), suggesting that the activation of cytotoxic T cells or NK cells may be impaired in vivo in these patients. The production of
immunosuppressive factors by RCC was investigated. Using immunohistochemistry, IL-10 was detectable in 10 of 21 tumour samples tested.
IL-10 was undetectable in the supernatant of cell lines derived from these RCCs. However, these cell lines or their conditioned medium (RCC
CM), but not normal renal epithelial cells adjacent to the RCC or breast carcinoma cell lines, were found to induce IL-10, as well as
prostaglandin E2 (PGE2) and tumour necrosis factor (TNF)a production by autologous or allogeneic peripheral blood mononuclear cells
(PBMCs) and monocytes. IL-10 production induced by RCC CM was found to be dependent on TNF-a and PGE2 since an anti-TNF-a antibody
(Ab) inhibited 40–70% of IL-10 production by monocytes, and the combination of anti-TNF-a Ab and indomethacin, an inhibitor of PGE2
production, inhibited 80–94% of RCC CM-induced IL-10 production by monocytes. The RCC CM of the five cell lines tested were found to
induce a down-regulation of the expression of HLA-DR and CD86, as well as a strong inhibition of mannose receptor-dependent endocytosis
by monocytes. The blockade of HLA-DR and CD86 expression was partially abrogated by indomethacin and anti-IL-10 Ab respectively, and
completely abrogated by an anti-TNF-a Ab. The inhibition of mannose receptor-dependent endocytosis was partially abrogated by an anti-IL-
10 Ab and completely abrogated by an anti-TNF-a Ab. These results indicate that RCCs induce IL-10, PGE2 and TNF-a production by
monocytes, which down-regulate the expression of cell-surface molecules involved in antigen presentation as well as their endocytic capacity.
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Correspondence to: JY Blaymedium supplemented with 2 mM glutamine, 200 U ml–1 peni-
cillin, 200 mg ml–1 streptomycin (Gibco Laboratories, Grand
Island, NY, USA) and 10% fetal calf serum (Biowittaker, Verviers,
Belgium). All these cell lines are regularly tested for mycoplasma
infection using a specific enzyme-linked immunosorbent assay
(ELISA) (Boehringer Mannheim, Meylan, France) and consis-
tently found to be negative.
PBMC, monocytes and lymphocytes preparation
Total peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized blood obtained from healthy volunteers and from
four patients with RCC in whom tumour cell lines (CAN, VER) or
tumour cell cultures (LEC, DUF) were obtained, using
Ficoll–Hypaque density-gradient centrifugation (Eurobio, Les
Ulis, France). Monocytes and lymphocytes were further purified
on a multistep Percoll gradient as previously described (Sallusto et
al, 1994). Around 85–90% of the cells in the monocyte-enriched
fraction were positive for CD14 expression using flow cytometry,
compared with less than 3% of the cells in the lymphocyte-
enriched population.
Conditioned medium (CM) of renal cell carcinoma and
other cell lines
Carcinoma cell lines were plated in 100-mm-diameter Petri dishes
at a density of 5 ´ 105 cells ml–1 in complete medium. After 2 days
of culture, supernatants were harvested, filtered through 0.22-mm
mesh, aliquoted and stored at –20°C for further investigations.
Each batch was tested for mycoplasma contamination and found to
be negative.
Culture conditions
PBMCs, monocytes and lymphocytes were cultured in RPMI with
10% FCS in 24-well flat-bottomed plates (Falcon Labware,
Oxnard, CA, USA) for the quantification of IL-10 production.
PBMCs (106), 4 ´ 105 monocytes and 8 ´ 105 lymphocytes
were plated in a final volume of 1 ml with 5 ´ 104 tumoral cells.
In transwell (Costar, Brumath, France) culture conditions, mono-
cytes were seeded in the upper compartment and tumoral cells
in the lower compartment of 24-well plates. Cultures with
conditioned medium (CM) were performed by addition of 5–80%
or 40% RCC CM according as specified. The positive control
for IL-10 production was obtained by addition of lipopolysaccha-
ride (LPS), (1 mg ml–1) to PBMCs, monocytes or lymphocytes
culture. Cells cultured in RPMI with 10% FCS alone were used as
negative control.
Supernatants were collected after 48 h as this time has been
reported to be the peak of IL-10 production by monocytes (de
Waal Malefyt et al, 1991).
Reagents
Purified human cytokines were used at the indicated concentra-
tions: rIL-1b (100 units per ml) was purchased from Innogenetics
(Zwijnaarde, Belgium); rTNF-a (100 ng ml–1), IL-6 (100 ng ml–1),
basic Fibroblast growth factor (FGFb) (0.1–100 ng ml–1) and
TGF-b (1–100 ng ml–1) from Genzyme Corporation (Boston, MA,
USA) and granulocyte–macrophage colony-stimulating factor
(GM-CSF) (1–100 ng ml–1) and-IL-10 from Schering Plough
Corporation (Dardilly, France). Neutralizing anti-IL-10 rabbit
polyclonal antibody was kindly provided by N Burdin (Schering
Plough Corporation, Dardilly, France). The anti-IL-10 monoclonal
antibody (Ab85) used in immunohistochemistry was kindly
provided by I Joab and used at a 1:200 final concentration (Emilie
et al, 1992; Voorzanger et al, 1996). Neutralizing anti-TNF-a
polyclonal antibody (IP-300) was purchased from Genzyme
Corporation and used at 10 mg ml–1 LPS from Escherichia coli
serotype 0111:B4 was used at 1 mg ml–1 (Sigma, St Louis, MO,
USA). Anti-HLA-DR, anti-CD14, anti-CD80, -CD45, -CD3 and 
-CD20 were purchased from Becton Dickinson, Pont de Claix,
France, anti-CD54 from Immunotech, Luminy, France and CD86,
anti-IL-10 (9D7) and rat isotype control from Pharmingen, San
Diego, CA, USA. G250, which stains specifically RCC tumour
cells (Oosterwijk et al, 1986), was kindly provided by Dr Fleuren
(Leiden, the Netherlands). Indomethacin (Sigma) was used at the
optimal concentration of 10 mM (Kambayashi et al, 1995). The
isotype control antibody for anti-IL-10 antibody (Ab85) was a
mouse IgG (R & D, Abingdon, UK; 10 mg ml–1). The isotype
control antibody for anti-TNF-a and anti-IL-10 antibodies used in
culture neutralization experiments was a rabbit polyclonal anti-
body (R & D, 10 mg ml–1).
Immunohistochemistry
Immunochemical stainings were performed using an indirect three-
step immunoenzymatic procedure with alkaline phosphatase (AP)
(Combaret et al, 1989). Briefly, air-dried cryostat sections were
fixed for 10 min in 4% paraformaldehyde at 4°C and incubated for
30 min with the primary antibody. After two washes in Tris-
buffered, saline (TBS) containing 0.2% bovine serum albumin
(BSA), slides were incubated for 30 min with AP-conjugated rabbit
anti-mouse immunoglobulins (Ig) (Dako, Trappes, France), washed
and incubated for 30 min with an AP-conjugated swine anti-rabbit
Ig (Dako). Revelation was performed using the AP substrate (naph-
thol AS MX phosphate, dimethyl formamide, levamisole and fast
red), before counterstaining with haematoxylin.
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Table 1 Cytokine pattern in supernatant of culture with RCC CM
TNF-a PGE-2 IL-10
(ng ml–1) (ng ml–1) (ng ml–1)
Conditioned medium (CM)
CAN 0.011 < 0.016 < 0.04
CHA 0.040 < 0.016 < 0.04
GUI 0.030 < 0.016 < 0.04
VER < 0.01 < 0.016 < 0.04
ACHN < 0.01 < 0.016 < 0.04
A-704 < 0.01 < 0.016 < 0.04
Caki-1 0.080 < 0.016 < 0.04
T47-D < 0.01 < 0.016 < 0.04
CM with monocytes
CAN 0.53 0.42 0.77
CHA 1.3 1.05 0.63
GUI 1.18 0.6 0.37
VER 0.95 0.95 0.35
A-704 0.54 1.37 1.21
ACHN 0.4 3.25 0.75
Caki-1 0.08 4.7 1.03
T-47D 0.05 0.016 < 0.04
None 0.054 0.02 < 0.04
LPS 2.6 3.5 1.13IL-10 immunosuppression in RCC 121
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Figure 1 RCC cryostat sections immunostaining (A–F). The antibodies used were Ab85 (anti-IL-10) (A), 2D1 (CD45) (B), G250 (specific for RCC tumoral
cells) (C), My-4 (CD14) (D), B1 (CD20) (E) and T3 (CD3) (F). The isotype-matched control showed the absence of background staining (data not shown).
Negative staining for IL-10 (H) in CD14+ (G) cells of normal renal parenchymaFlow cytometric analysis
Membrane staining
Flow cytometric analysis was carried out by incubating 5 ´ 104–
105 cells for 20 min in 50 ml of phosphate-buffered saline (PBS)
with 1% BSA and 0.1% sodium azide on ice with optimal concen-
trations of the above-mentioned antibodies coupled to phycoery-
thrin (PE). Cells were washed three times with PBS 1% BSA 0.1%
sodium azide. The phenotype of the cells was analysed using a
flow cytometer (FACScan).
Intracellular staining
Intracytoplasmic staining of IL-10 was performed after 48 h
culture of PBMC with RCC cell lines in presence of Monensin (2
mM) (Sigma) to avoid cytokine secretion. Cells were permeabilized
for 5 min in saponin buffer (0.33%) and labelled with an anti-IL-
10 rat antibody coupled to PE (9D7) (Pharmingen) for 20 min
according to the manufacturer’s protocol. After three washes,
intracytoplasmic IL-10 expression was analysed on a FACScan.
Labelling specificity was assessed either with a rat IgG control
antibody (R & D) staining or by preincubating 9D7 with a 100-
fold excess of recombinant IL-10 before PBMC staining.
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Figure 2 Mean IL-10 production in co-culture of autologous PBMCs (106
cells ml–1) with four different RCC cell lines (CAN tum, VER, LEC, DUF) or
with normal renal epithelial cells (CAN nor) (5 ´ 104 cells per well). Positive
control was performed using LPS for each patient. This experiment is
representative of three performed with different batch of PBMCs. IL-10
secretion by PBMCs treated with LPS or co-cultured with RCC CM is
superior to that of PBMCs cultured with normal renal epithelial cells
(Student’s t-test P = 0.001)
Figure 3 Mean IL-10 production in co-culture of allogeneic healthy donor
PBMCs (106 cells during 48 h) (n), purified monocytes (4 ´ 105 cells during
48 h) (n n) and lymphocytes (8 ´ 105 cells during 48 h) (n) with six different
RCC cell lines (CAN, CHA, VER, Caki-2, ACHN, A-704), one normal renal
epithelial primary culture (CAN nor) and one breast carcinoma cell line
(MCF-7). Mean IL-10 production by epithelial cells alone (carcinoma cells or
normal renal epithelial cells (n n). Positive control was performed using LPS
(1 mg ml–1). This experiment is representative of five performed with different
healthy donor PBMCs. IL-10 secretion by PBMCs (or monocytes) treated
with LPS or cultured with RCC is significantly superior to that of PBMCs (or
monocytes) co-cultured with breast carcinoma cell lines or normal renal
epithelial cell cultures (Student’s t-test, P < 0.01)
Figure 4 Intracytoplasmic IL-10 expression by allogeneic PBMCs cultured
either in medium or with an RCC cell line (CHA coc as an example) in the
presence of monensin (2 mM) was characterized by staining with a PE-
conjugated anti-IL-10 antibody (9D7) (B and D). The specificity of the
labelling was assessed by preincubation of 9D7 with a 100-fold excess of IL-
10 [9D7IL-10] (A and C). A control performed with a rat IgG1 control antibody
was superimposable on the [9D7-IL-10] labelling (data not shown)
Figure 5 Mean IL-10 production by allogeneic purified monocytes
(4 ´ 105 cells per ml) co-cultured with RCC cell lines (5 ´ 104 cells per well)
( ) or through a permeable membrane of transwell ( ) or with 40% RCC
CM (n). This experiment was representative of five performed with different
healthy donors
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)Cytokine ELISA
Cell supernatants, collected after 48 h of culture, were tested for
the presence of IL-10 using a two-site sandwich ELISA method as
previously described (Abrams et al, 1992). The detection limit of
IL-10 ELISA is 0.04 ng ml–1. TNF-a and PGE2 levels in co-culture
supernatants were measured using two-site sandwich immuno-
assays purchased from Immunotech (Marseille, France) for TNF-a
and from Amersham (Les Ulis, France) for PGE2. The sensitivity
of the tests was 10 pg ml–1, and 16 pg ml–1 for TNF-a and PGE2
respectively.
RT-PCR for IL-10
RT-PCR for IL-10 mRNA was performed as follows: precycle at
94°C for 3 min; cycles 1–40 at 94°C for 1 min (strand prepara-
tion), 58°C for 2 min (annealing) and 72°C for 3 min (primer
extension). Then, the reaction was held at 72°C for 10 min. All
reactions were performed with a Perkin Elmer DNA thermal
cycler model 480. The primers for IL-10 mRNA were AGAAG-
GCATGCACCAGCTCAGCA (3¢) and TTTTGGAGACCTC-
TAATTTATG (5¢). Negative control was performed without
cDNA adjunction in the master mix reagent. The positive control
was the cDNA of the BJAB cell line (kindly provided by N
Burdin, Schering Plough Corporation, Dardilly, France).
Endocytosis
Endocytosis was analysed using a previously described technique
(Sallusto et al, 1995). After 48 h of culture, with or without RCC
CM or the indicated antibodies and reagent, monocytes were
washed three times and resuspended in 10% FCS medium buffered
with 25 mM hepes at 37°C. After 10 min, fluorescein isothio-
cyanate (FITC)–dextran (DX-FITC, Molecular probe, Eugene,
OR, USA) was added at the final concentration of 10 mg ml–1 for
30 min, at 37°C or at 4°C (control). The cells were then washed
four times with cold PBS containing 1% FCS and 0.1% sodium
azide and analysed on a FACScan.
IL-10 immunosuppression in RCC 123
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Figure 6 Mean IL-10 production by purified monocytes cultured with RCC CM (40%) in medium alone (n), with a polyclonal anti-TNF-a Ab (10 mg ml–1 () ,
with indomethacin (10 mM) ( ) or with the combination of indomethacin +anti-TNF-a Ab ( ). IL-10 production is significantly lower in the presence of anti-TNF-
a Ab (P < 0.01) but not indomethacin alone (P > 0.1). However, IL 10 secretion is significantly lower with anti-TNF-a+indomethacin compared with anti-TNF-a
Ab alone in all cell lines (Student’s t-test, P < 0.05)Phagocytosis
Monocytes were cultured for 48 h with or without RCC CM or the
indicated antibodies and reagent. During the last 4 h of the culture,
0.5 mm latex beads coupled to FITC (1:400) (Polysciences,
Warrington, PA, USA) were added to the medium. To analyse the
phagocytic capacity of monocytes, cells were recovered and
washed three times with PBS. The phagocytosis of the latex
beads–FITC was evaluated on a FACScan analyser.
Statistics
Statistical comparison between samples were performed using
Student’s  t-test or Student’s paired t-test.
RESULTS
IL-10 production in renal cell carcinomas
Immunohistochemical analysis of 21 RCC tumour cryostat
sections was performed with an anti-IL-10 mAb (Ab 85) using a
technique already reported elsewhere (Emilie et al, 1992;
Voorzanger et al, 1996). A positive staining for IL-10 was
observed in ten of these 21 tumours (47%) (Figure 1A and B). In
the surrounding normal renal cell parenchyma, no positive
staining for IL-10 was observed (Figure 1G and H). Ten of these
21 RCC tumour samples (including seven IL-10-positive tumours
by immunohistochemistry) were found to be positive for IL-10
mRNA expression using RT-PCR, whereas the four non-tumoral
124 C Ménétrier-Caux et al
British Journal of Cancer (1999) 79(1), 119–130 © Cancer Research Campaign 1999
Control CD80
CD54 CD86
CD14
HLA-DR
10
0 101 102 103 100 101 102 103 100 101 102 103
100 101 102 103 100 101 102 103 100 101 102 103
Fluorescence intensity (PE)
Figure 7 FACScan analysis of CD14, CD54, CD80, CD86 and HLA-DR expression on monocytes cultured in medium alone (solid line) or with RCC CM (VER)
(dotted line). Similar results were obtained with other cell lines (Caki-1, Caki-2, CHA, CAN) and with co-cultureskidney samples tested were negative for IL-10 mRNA expression
(data not shown). Morphological and topographical examination
suggested that IL-10-positive cells are in part infiltrating non-
tumoral mononuclear cells (Figure 1B, D and F).
RCC cell lines induce IL-10 production by monocytes
IL-10 was undetectable in the supernatant of all ten RCC cell lines
tested (see Figures 2 and 3 for seven representative cell lines).
RCC cell lines were co-cultured for 48 h with autologous PBMCs
or allogeneic PBMCs from healthy donors. High levels of IL-10
were detectable in the supernatant of the co-cultures of RCC cell
lines with either autologous (Figure 2) or allogeneic PBMCs
(Figure 3), as well as in the positive controls, i.e. LPS-treated
autologous PBMCs (Figure 2) or allogeneic PBMCs (Figure 3). Of
note, RCC-induced IL-10 secretion by autologous PBMCs was
lower than that of allogeneic PBMCs in all cell lines tested,
possibly because autologous PBMCs were stored frozen prior to
the experiment, whereas allogeneic PBMCs were collected and
used immediately (Figures 2 and 3). In contrast, IL-10 was unde-
tectable in the supernatant of the primary culture of normal renal
epithelial cells (CAN nor) co-incubated with autologous (Figure 2)
or allogeneic PBMCs (Figure 3). Similarly, IL-10 was unde-
tectable in co-cultures of allogeneic PBMCs with breast cell carci-
noma cell lines (Figure 3). Purified lymphocytes (< 3% CD14+)
failed to produce IL-10 in the presence of LPS or RCC cell lines
(Figure 3), whereas purified monocytes (85–90% CD14+)
produced IL-10 in both of these conditions (Figure 3).
Intracytoplasmic staining with an anti-IL-10 antibody (9D7)
demonstrated that only monocytes secreted IL-10 under stimula-
tion with RCC cell lines (Figure 4B). The specificity of this
staining was assessed by preincubation of anti IL-10 with a 100-
fold excess of recombinant IL-10 before PBMC staining (Figure
4A). Monocytes also produced IL-10 when cultured with RCC cell
IL-10 immunosuppression in RCC 125
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Figure 8 CD14, HLA-DR and CD86 expression by allogeneic monocytes cultured in medium (dotted line) or with 40% RCC CM (VER as an example) (solid
line) alone or in presence of indomethacin (10 mM) or polyclonal antibodies (anti-IL-10 Ab and anti-TNF-a Ab) (10 mg ml–1). The mean fluorescence intensity
(MFI) of the isotype controls ranged from 100 to 101
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3lines in a transwell system or in the presence of RCC CM, indi-
cating that IL-10 production was induced at least in part by a
soluble factor produced by RCC cell lines (Figure 5). IL-10
production correlated with the percentage of RCC CM added in
the culture, e.g. <0.04ng ml–1 with 5% RCC CM, 0.328ng ml–1
with 10%, 0.619ng ml–1 with 20%, 0.88ng ml–1 with 40% and
1.02ng ml–1 with 80% in a representative experiment with the
conditioned medium of the CAN cell line. All subsequent experi-
ments were performed with allogeneic monocytes cultured with
40% RCC CM.
IL-10 production is mediated by TNF-aand PGE2
TNF-aand PGE2 have been reported to induce IL-10 production
by monocytes and macrophages (Wanidworanum and Strober,
1993; Kambayashi et al, 1995). Heat inactivation (100°C, 30min)
of RCC CM reduced partially (32% to 60%) IL-10 production by
the eight different RCC CM tested, suggesting the co-involvement
of a heat-insensitive molecule. Indeed, high levels of TNF-aand
PGE2 were detectable in the supernatant of monocytes cultured in
the presence of RCC but not with breast carcinoma conditioned
medium (Table 1). A polyclonal anti-TNF-aAb blocked 40–70%
of the production of IL-10 by monocytes incubated with the RCC
CM of CAKI-1 and VER whereas indomethacin (an inhibitor of
PGE-2 synthesis) induced a minor inhibition of IL-10 production
(Figure 6). Anti-TNFaAb significantly reduced the production of
PGE-2 by monocytes incubated with Caki-1 or VER CM (70.8 ±
12%; range = 57%–85%, P< 0.05 using Student’s t-test in three
experiments), indicating that PGE2 production by monocytes is in
part induced by TNF-a. The combination of anti-TNF-aAb and
indomethacin inhibited, at least additively, IL-10 production
(80–94%) (Figure 6). These results indicate that TNF-aand PGE2
are responsible for the induction of IL-10 production by mono-
cytes incubated in the presence of RCC CM.
Importantly, the supernatant of the six RCC lines tested
contained only low or undetectable TNF-alevels and no PGE2
(Table 1). This suggests that RCC cell lines produce a soluble
mediator which induces TNF-aand PGE2 production by mono-
cytes, both molecules acting additively to induce IL-10 production
through an autocrine loop.
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Figure 9Endocytic capacity (mannose receptor mediated) of monocytes evaluated by dextran–FITC (DX–FITC) incorporation (10mg ml–1)0 at 37°C for 30min.
Comparison of endocytosis of DX–FITC in medium (dotted line) or in presence of 40% RCC CM (VER as an example) (solid line) alone or in the presence of
polyclonal antibodies (anti-TNF-aAb and anti-IL-10 Ab) (10mg ml–1) or indomethacin (10mM). A non-related polyclonal antibody (see Materials and methods)
had no effect on endocytic capacity (not shown)Phenotypic and functional alterations of monocytes by
RCC: role of TNF-a, PGE2 and IL-10
Phenotypic modifications
Monocytes were collected after 2 days of culture with RCC CM
and tested for CD14, CD54, CD80, CD86 and HLA-DR expres-
sion. The conditioned medium of the five RCC cell lines tested
(Caki-1, Caki-2, CHA, VER, CAN), but not of breast carcinoma
cell lines (T47-D, MCF-7, SK-BR3) (not shown), induced a signif-
icant decrease in HLA-DR, CD54 and CD86 expression, whereas
CD14 an CD80 expression were unaffected (Figure 7). Anti-IL-10
Ab, but not a control polyclonal Ab, partially reversed the inhibi-
tion of CD86 expression induced by RCC CM, without affecting
HLA-DR expression. Indomethacin (10 mM) partially reversed the
decrease in HLA-DR expression without affecting CD86 expres-
sion (Figure 8). The decrease in CD86 and HLA-DR expression
induced by RCC CM could be completely abrogated by the addi-
tion of an anti-TNF-a neutralizing Ab (Figure 8) whereas the poly-
clonal control Ab had no effect (not shown).
Modulation of endocytosis and phagocytosis capacities by
RCC CM
The endocytic capacity of monocytes cultured in RPMI–10% FCS
for 48 h was evaluated using dextran–FITC incorporation (Figure
9), which was inhibited by incubation at 4°C or with a solution of
mannane (0.3 mg ml–1) (data not shown). The addition of RCC CM
(VER and Caki-1 cell lines), but not breast carcinoma CM (data
not shown), completely inhibited the endocytic capacity of
monocytes (Figure 9). This effect was partially reversed by an
anti-IL-10 Ab, and completely reversed by an anti-TNF-a Ab,
whereas polyclonal control Ab had no effect (Figure 9).
In contrast, the capacity of monocytes to phagocyte 0.5 mm latex
beads coupled to FITC was strongly enhanced in presence of the RCC
CM (VER and Caki-1 cell lines) (Figure 10). Anti-IL-10 Ab alone
partially abrogated this effect of RCC CM (Figure 10). Although
indomethacin and anti-TNF-aalone had no effect, the combination of
anti-IL-10 Ab with indomethacin + anti-TNF-a Ab synergistically
blocked the increase in phagocytic capacity mediated by RCC CM.
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Figure 10 Phagocytosis of latex beads (0.5 mm) coupled to FITC by monocytes cultured in medium (dotted line) or in the presence of 40% RCC CM (VER as
an example) (solid line) alone or in the presence of indomethacin (10 mM) or polyclonal antibodies (anti-TNF-a Ab and anti-IL-10 Ab) (10 mg ml–1). A non-related
polyclonal antibody (see Materials and methods) had no effect on phagocytic capacity (not shown)
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The objectives of this study were to investigate the production by
RCC tumours of immunosuppressive factors that may potentially
affect the anti-tumour immune response. The results presented
show that IL-10, an immunosuppressive cytokine, is detectable by
immunohistochemistry in RCC tumours but not produced by RCC
cells purified from these biopsies. The production of IL-10 by non-
tumoral cells in biopsies has also been reported in other tumour
models such as non-Hodgkin’s lymphoma (Voorzanger et al,
1996). However, RCC cell lines, but not normal renal epithelial
cells or breast carcinoma cell lines, were found to produce (a)
soluble factor(s) which triggers the production of IL-10 by autolo-
gous and allogeneic monocytes in vitro.
These results are in agreement with previous observations
showing that IL-10 transcripts are detectable in tumour-infiltrating
leucocytes of RCC tumours by RT-PCR (Filgueira et al, 1993;
Mauerer et al, 1995; Nakagomi et al, 1995; Wang et al, 1995).
However, in this model, monocytes were found to be the major
IL-10 producers among PBMCs, whereas purified lymphocytes
failed to produce IL-10 in the same conditions. The observation
that normal renal epithelial cells are not able to induce IL-10
production in vitro is consistent with the absence of IL-10 produc-
tion by the normal adjacent renal parenchyma and indicates that
the capacity to induce IL-10 production is highly correlated with a
malignant phenotype for renal epithelial cells.
It is also important to notice that IL-10 production was signifi-
cantly higher when monocytes and tumoral cells were in the same
well as compared with culture in a transwell system, without
contact between monocytes and tumoral cells. This observation
could be explained by greater concentration of soluble factors at the
contact of RCC cells, allowing the strongest activation of mono-
cytes. However, we cannot exclude the possibility that a transmem-
brane molecule expressed at the surface of RCC cells may
contribute to stimulate monocyte production of TNF-a and IL-10.
The results presented here show that RCC CM also elicited the
production of PGE2 and TNF-a by monocytes and that anti-
TNF-a Ab and indomethacin, an inhibitor of PGE2 production, at
least additively inhibited IL-10 production induced by RCC CM.
TNF-a and PGE2 are well-known inducers of IL-10 production
(Wanidworanum and Strober, 1993; Kambayashi et al, 1995;
Huang et al, 1996) and recombinant TNF-a and PGE2 were found
to act synergistically in the induction of IL-10 production by
monocytes in vitro (not shown). However, the capacity of
indomethacin to affect IL-10 production has not been reported.
Although a role for other metabolites of arachidonic acid cannot
be excluded, these results strongly suggest that TNF-a and PGE2
are involved in the induction of IL-10 production by monocytes
elicited by RCC CM. An anti-TNF-a Ab was found capable of
blocking RCC-mediated PGE2 production by monocytes, in agree-
ment with previous observations showing that TNF-a induces
PGE2 production (Bachwich et al, 1986; Lehmmann et al, 1988;
Alleva et al, 1993). Taken together, these results indicate that
TNF-a is a central mediator for the induction of PGE2 and IL-10
production by monocytes in this model. The TNF-a/PGE2/IL-10
cascade is induced by RCC cells but not by normal renal epithelial
cells or by the breast carcinoma cell lines tested.
In the present study, the addition of RCC CM potently affected
the phenotype and function of peripheral blood monocytes
cultured in vitro. RCC CM induced a down-regulation of both
CD86 and HLA-DR expression on monocytes, these phenomena
being reversed partially by an anti-IL-10 Ab and indomethacin
respectively. This suggests that RCC CM-mediated inhibition of
HLA-DR and CD86 expression is in part mediated by PGE2 and
IL-10 respectively. Indeed, PGE2 and recombinant IL-10 respec-
tively block HLA-DR and CD86 expression in vitro (data not
shown), in agreement with previous reports (de Waal Malefyt et al,
1991). However, indomethacin may also block other arachidonic
acid mediators that might play a role in this phenomenon.
Although the anti-IL-10 Ab tested was capable of antagonizing the
inhibition of CD86 induced by similar concentrations of recombi-
nant IL-10 (100 U ml–1) (not shown), it failed to abrogate the effect
of RCC CM, suggesting the existence of other inhibitory factors
elicited by RCC CM. Indeed, an anti-TNF-a Ab abrogated the
down-regulation of CD86 and HLA-DR expression induced by
RCC CM much more efficiently than anti-IL-10 Ab or
indomethacin. To our knowledge, this effect of an anti-TNF-a Ab
has not been previously described. Anti-TNF-a may act here by
inhibiting IL-10 and PGE2 production by monocytes, which may
result in a more efficient inhibition than the PGE2 and IL-10
inhibitors used in this study.
In addition to these phenotypic alterations, the supernatant of
RCC cell lines induced a strong down-regulation of endocytosis
mediated by mannose receptor, a phenomenon that was also partly
abrogated by an anti-IL-10 and completely inhibited by anti-
TNF-a Ab. Endocytosis is an initial step allowing exogenous
antigen processing within the endocytic compartment, followed by
antigen presentation by MHC class II receptors (for review see
Watts, 1997). The loss of CD86 and HLA-DR expression on
monocytes induced by RCC CM may have important functional
consequences for the immune response against RCC cells. In vivo,
in man, the lack of expression of HLA class II antigens in RCC
tumours has been associated with a lack of response to
immunotherapy with IL-2 (Cohen et al, 1987; Rubin et al, 1989).
The results presented here suggested that the loss of HLA-DR
expression may be induced by RCC tumour cells themselves. The
simultaneous inhibition of mannose receptor-mediated endocy-
tosis by the TNF-a/PGE2/IL-10 cascade induced by RCC CM may
further contribute to impair the antigen presentation properties of
monocytes in vivo.
Finally, in contrast to these inhibitory properties, RCC CM were
found to increase the phagocytic capacity of monocytes, an effect
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Figure 11 A proposed scheme for the cytokine cascade elicited by RCCwhich was partially blocked by anti-IL-10 Ab. Although
indomethacin (not shown) and anti-TNF-a had no effect, the
combination of anti-IL-10 Ab, indomethacin and anti-TNF-a Ab
synergistically blocked the increase in phagocytic activity. This
synergistic effect may result from the inhibition of IL-10 produc-
tion induced by anti-TNF-a and indomethacin. This is in agree-
ment with recent reports showing that IL-10 increases the
phagocytic capacity of macrophages (Capsoni et al, 1995;
Hashimoto et al, 1997).
The soluble factor(s) responsible for the activation of the
TNF-a/PGE2/IL-10 cascade are not yet characterized. RCC CM
contain only low or undetectable levels of these mediators, indi-
cating that RCC cell lines produce (a) soluble mediator(s) capable
of inducing the production of TNF-a by monocytes (Figure 11).
The factor(s) responsible for the cytokine cascade induced by RCC
CM is (are) currently under investigation since cytokines previ-
ously reported to be produced by RCC, i.e. TGF-b1 FGFb, IL-6,
IL-8, TGF-a and GM-CSF, were found unable to induce IL-10
production by monocytes (not shown).
Taken together, these results indicate that RCCs induce the
production of a cytokine cascade TNF-a/PGE2/IL-10 which
inhibits the expression of surface molecules involved in the
antigen-presenting function of monocytes as well as their mannose
receptor-mediated endocytic capacity. These phenomena may
interfere with the spontaneous and therapeutic immune response
against RCC tumours in vivo in patients.
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